


## Bozepinib

Cat. No.:	HY-118032
CAS No.:	1207993-83-6
Molecular Formula:	C <sub>20</sub> H <sub>14</sub> Cl <sub>2</sub> N <sub>6</sub> O <sub>5</sub> S
Molecular Weight:	521.33
Target:	Apoptosis; Autophagy; JNK; ERK
Pathway:	Apoptosis; Autophagy; MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Bozepinib is a PKR (RNA-dependent protein kinase) activator and potently inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces PKR-mediated apoptosis and synergizes with IFN $\alpha$  to trigger apoptosis, autophagy and senescence. Bozepinib also demonstrates in vivo antitumor and antimetastatic efficacy in xenografted nude mice<sup>[1][2]</sup>.

### REFERENCES

- [1]. Marchal JA, et al. Bozepinib, a novel small antitumor agent, induces PKR-mediated apoptosis and synergizes with IFN $\alpha$  triggering apoptosis, autophagy and senescence. *Drug Des Devel Ther.* 2013 Oct 29;7:1301-13.
- [2]. Ramírez A, et al. HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound. *Oncotarget.* 2014 Jun 15;5(11):3590-606.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA